Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8741015 | Journal of Microbiology, Immunology and Infection | 2017 | 14 Pages |
Abstract
We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5Â h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kazufumi Takamatsu, Satoshi Marumo, Motonari Fukui, Atsuko Hata,